Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5484-5493

  Xiong, Zhengming ^a   Gharagozlou, Soheila ^a,b   Vengco, Isabelita ^a   Chen, Wei ^a,b   Qhlfest, John R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EVALUATION; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; METASTASIS; METHODOLOGY; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOTHERAPY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 53049095387     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4139     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Engel J, Eckel R, Aydemir U, et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1186-95.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
4. Schroder K, Sweet MJ, Hume DA. Signal integration between IFNγ and TLR signalling pathways in macrophages. Immunobiology 2006;211:511-24.
5. Sester DP, Brion K,Trieu A, et al. CpG DNA activates survival in murine macrophages throughTLR9 and the phosphatidylinositol 3-kinase-Akt pathway. J Immunol 2006;177:4473-80.
6. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. CurrTop Microbiol Immunol 2006;311:17-58.
7. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
8. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999;59:5429-32.
9. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000;6:2469-73.
10. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8( + ) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247-53.
11. Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neurooncol 2006;8:60-6.
12. Pashenkov M, Goess G, Wagner C, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24:5716-24.
13. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for thetreatment and prevention of spontaneous breast tumors. Cancer Res 2007;67:1326-34.
14. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003;21:873-86.
15. Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005;12:778-88.
16. Wu A, Oh S, Ericson K, et al. Transposon-based interferon γ gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 2007;14:550-60.
17. Fallarino F, Puccetti P. Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur J Immunol 2006;36:8-11.
18. Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITRantibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006;66:4904-12.
19. Geurts AM,Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beautytransposon system. Mol Ther 2003;8:108-17.
20. El Andaloussi A, Sonabend AM, HanY, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006;54:526-35.
21. Grauer OM, Nierkens S, Bennink E, et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007;121:95-105.
22. Gasparini G, Longo R,Torino F, Morabito A. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;16 Suppl 4:iv28-36.
23. Gabos Z, Sinha R, Hanson J, et al. Prognosticsignificance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-63.
24. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003;3:569-81.
25. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000;97:7482-7.
26. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Preexisting antiadenoviral immunityis not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum GeneTher 2001;12:839-46.
27. Abordo-Adesida E, Follenzi A, Barcia C, et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum GeneTher 2005;16:741-51.
28. Cheeran MC, Gekker G, Hu S, Min X, Cox D, Lokensgard JR. Intracerebral infection with murine cytomegalovirus induces CXCL10 and is restricted by adoptive transfer of splenocytes. J Neurovirol 2004;10:152-62.
29. Cheeran MC, Gekker G, HuS, Palmquist JM, Lokensgard JR. Tcell-mediated restriction of intracerebral murine cytomegalovirus infection displaysdependence upon perforin but not interferon-γ. J Neurovirol 2005;11:274-80.
30. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG. Gene therapy and targeted toxins for glioma. Curr GeneTher 2005;5:535-57.
31. Fecci PE, Mitchell DA, Archer GE, et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol2003;64:161-76.
32. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR.
33. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-14.
34. Wu A, Oh S, Gharagozlou S, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007;30:789-97.
35. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006;12:4294-305.
36. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105:430-7.
37. Yamanaka R, Homma J,Yajima N, et al. Clinical evaluation of dendriticcell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11:4160-7.
38. de Vries IJ, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivityskin biopsies after dendriticcell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-87.